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State policies aimed at preventing drug abuse, regulating professional practice, and improving patient care can 
either enhance or interfere with pain management.  Three evaluations over a six-year period by the University 
of Wisconsin Pain & Policy Studies Group (PPSG) show improvement in state policies governing the medical 
use of opioid medications.  This Progress Report Card (Progress Report Card 2006) uses evidence from policy 
research to grade states’ policies from A to F.  Along with the companion analysis of each state’s policies 
(entitled Achieving Balance in Federal and State Pain Policy: A Guide to Evaluation (Third edition)) (Evaluation 
Guide 2006), the Progress Report Card 2006 can be used by state agencies and pain relief advocates to develop 
plans to further improve state pain policies.
The evidence used to create the Progress Report Card 2006 comes from a systematic, criteria-based, research 
evaluation of the best information available to the PPSG.  We hope that our findings, conclusions, and 
recommendations will stimulate individuals, organizations, and state governments to work together to evaluate 
or re-evaluate their policies regarding pain management and to take the necessary steps to improve and 
implement them.  
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The Pain & Policy Studies Group
The mission of the Pain & Policy Studies Group is to achieve more balanced international, national 
and state policies so that patients’ access to pain medications is not compromised by efforts to 
prevent diversion and drug abuse.
The following recent contributions of the PPSG are described in publications, available at  
www.painpolicy.wisc.edu:
◆  Pain policy workshops for members of state medical boards, and research demonstrating 
improvements in knowledge and attitudes about pain management and public policy.
◆  Research showing that state policies improved when boards use a model pain policy.
◆  Content evaluation of federal and state policy.
◆  Evaluation of policies influencing the use of controlled substances for treatment of pain in 
persons with a history of substance abuse.
◆  Status of state prescription monitoring programs.
◆  Efforts of state medical boards to improve and communicate pain policies to physicians.
◆  Commentary on the relation between pain management and increasing abuse of prescription 
pain medications.
◆  Analysis of the extent that pain medications are stolen from the licit drug distribution system.
◆  A reassessment of trends in medical use and abuse of opioid pain medications.
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ExECuTIvE SuMMARy
Pain, sometimes severe and debilitating, is associated with a variety of diseases including 
cancer, sickle-cell anemia, HIV/AIDS, and other chronic conditions.  Adequate pain relief 
contributes to improved health and can restore quality of life.  Unfortunately, inadequate 
relief of pain continues to occur all too often.  People often react with disbelief or surprise that 
painful conditions can go unrelieved with the modern medicine available in the U.S.  The 
devastating effects of chronic pain are tragic and expensive, and ironic in light of existing 
knowledge about pain management which too often does not reach those in need.  
Most if not all pain can be relieved, but only if knowledgeable healthcare professionals are 
able to properly use the many treatments that are safe and effective. Opioid pain medications 
have a well-recognized role in managing pain, particularly when it is severe.  But opioids also 
have a potential for abuse.  The controlled substances and professional practice policies that 
have been enacted to govern these medications and prevent abuse always come into play when 
health professionals use opioids to relieve pain.  In fact, governments are obligated not only to 
establish a system of drug controls to prevent abuse and diversion; they must also ensure their 
medical availability.  This is the Central Principle of Balance, which is the foundation of this 
research report.  Balanced policies include those with a potential to enhance pain management 
while avoiding the potential to interfere with such treatment.
Some states – but far from all – have adopted policies which recognize that controlled 
substances are necessary for public health, that pain management is part of quality medical 
practice, that medical education should include pain management and palliative care, and that 
patient care facilities have a responsibility to assess and treat pain.  
But in some states, pain treatment using opioids is unduly restricted by policies reflecting 
medical opinions that were discarded decades ago.  Practices that would be medical mistakes 
by today’s standards include requiring opioids to be a treatment of last resort, equating the use 
of opioids to manage pain with drug addiction, requiring “drug holidays,” and restricting the 
amount of medication that can be prescribed at one time regardless of patient need; yet such 
standards are common in today’s state policies.  Indeed, many states are now adopting model 
policies that avoid creating these potential barriers.  
In addition, for decades physicians have reported being reluctant to prescribe opioids because of 
fear of the stress, expense, and consequences of being investigated by licensing agencies or law 
enforcement.  These fears have profound implications for practitioners’ willingness to consider 
these medications as a viable treatment option and can, as a result, hinder patient access to 
adequate pain relief.  A number of states have adopted model policies that reassure licensees; in 
other states, policy remains silent.  
The focus of this report is the extent that policies which influence pain management contain 
language that potentially enhances or impedes pain management.  A research methodology was 
developed to grade each state based on the quality of its pain policy; state grades are presented 
for 2000, 2003, and 2006, to allow study of policy change over time.
The report concludes that state pain policies are becoming more balanced:
• Michigan and Virginia have an A and are the most balanced pain policies in the country
• 82% of states now have a grade above a C
• 19 states had positive grade change since 2003
• Rhode Island showed the greatest improvement, increasing from a D+ to B
• no state’s grade decreased over time
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The significant amount of policy improvement that occurred between 2003 and 2006 was the 
result of: (1) state healthcare regulatory boards adopting policies encouraging pain management, 
palliative care, or end-of-life care, and (2) state legislatures repealing restrictive or ambiguous 
policy language, including repealing multiple- or single-copy prescription programs.
The momentum for positive policy change, first reported in 2003, has endured, supporting the 
conclusion that government agencies continue to recognize the need to remove regulatory 
barriers and encourage appropriate treatment of pain.  To achieve more balanced and consistent 
pain policy, most states face the challenge not only of adopting positive policies, but of removing 
restrictive language from legislation. Experience around the country is showing that a valuable 
state governmental mechanism to achieve balanced policy is the use of task forces, advisory 
councils, and summit meetings to examine state pain policy.  This Progress Report Card, used in 
conjunction with Achieving Balance in Federal and State Pain Policy: A Guide to Evaluation (Third 
edition), provides a framework for deciding which policies should be removed, as well as models 
to guide the development of new and more balanced policies.  Balance in pain policy can be 
achieved and maintained if policymakers, healthcare professionals, and regulatory agencies 
work together and take advantage of the policy resources that are available.  In this way, we 
can establish a more positive regulatory and practice environment for the relief of pain in all 
patients, including those who are challenged by cancer, HIV/AIDS, sickle-cell anemia, and 
other painful conditions.
ExECuTIvE SuMMARy
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unrelieved Pain Continues to Burden Americans
It is well-documented that unrelieved pain continues to be a serious public health problem for 
the general population in the United States.1-8  This issue is particularly salient for children, 9-12 
the elderly,13-16 minorities,17-21 patients with active addiction or a history of substance abuse,22-25 
developmental disabilities,26,27 as well as for those with serious diseases such as cancer,28-33  
HIV/AIDS,9,34-38 or sickle-cell anemia.39-41  Clinical experience has demonstrated that adequate 
pain management leads to enhanced functioning and quality of life, while uncontrolled 
chronic pain contributes to disability and despair.
Pain can be Relieved
There are many effective drug and non-drug approaches to manage pain, which vary according 
to the individual needs of the patient.  However, there is a general medical and regulatory 
consensus that opioid analgesics (sometimes called by the archaic legal name, “narcotics”) are 
necessary to maintain public health;42 and that they are a mainstay of pain treatment for cancer 
and HIV/AIDS, particularly if pain is severe.28,33,43-47  Their use for the relief of a variety of 
chronic non-cancer pain conditions is also clinically beneficial.48,49  
The Gap Between knowledge and Practice
Medical science has contributed important new knowledge about pain management in the 
last 25 years, but incorporation of this knowledge into practice has been slow and remains 
incomplete.  A gap exists between what is known about pain management and what is done 
by healthcare professionals and institutions.  Whether a particular patient can obtain adequate 
pain relief depends on many factors in the healthcare and drug regulatory system; these 
factors, such as professional and institutional practices, can be influenced either positively or 
negatively by policy.  The connection between policy, professional and institutional practices, 
and patient care is complex, but the overarching public health goal is to develop policies that 
(if implemented) can enhance healthcare for patients, including pain treatment, and to avoid 
policies that can interfere in that care.  Policies that encourage pain management and consider 
it to be an expected part of healthcare practice are preferable to those policies that provide 
no positive guidance to professionals treating patients’ pain, or which are based on incorrect 
scientific knowledge and that establish unnecessary or unduly strict prescribing requirements.
Influence of Drug Abuse Control Policy
Opioid medications also have a potential for abuse.  Consequently, opioids and the healthcare 
professionals who prescribe, administer, or dispense them are regulated pursuant to federal and 
state controlled substances policies, as well as under state laws and regulations that govern 
professional practice.50,51  Such policies are intended only to prevent illicit trafficking, drug 
abuse, and substandard practice related to prescribing and patient care; however, in some states 
these policies go well beyond the usual framework of controlled substances and professional 
practice policy, and can negatively affect legitimate medical practices and create undue burdens 
for practitioners and patients.52-54
Some state policies that do not conform to or conflict with current standards of professional 
practice can interfere with pain management by:
• Unduly restricting the amounts that can be prescribed and dispensed,
• Unduly restricting the period for which prescriptions are valid,
• Restricting access to pain patients who also have a history of substance abuse,
• Requiring special government-issued prescription forms only for the medications that 
are capable of relieving pain that is severe, 
• Requiring opioids to be a treatment of last resort, and
• Using outdated definitions that confuse pain management with addiction.
INTRoDuCTIoN
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Further, policies that have been recommended to encourage pain management are frequently absent from state 
policies.  For example, some states have not yet adopted policies which recognize that:
• Controlled substances are necessary for the public health (as does federal law).42
• Pain management is an integral part of the practice of medicine (as does the Federation of State Medical 
Board’s Modern Medical Practice Act).55
• Controlled substances are an essential part of legitimate professional practice (as does the Federation of State 
Medical Board’s Model Policy for the Use of Controlled Substances for the Treatment of Pain).56
• Physicians should not fear regulatory sanctions for appropriately prescribing controlled substances for pain 
(as does the Federation of State Medical Board’s Model Policy for the Use of Controlled Substances for the 
Treatment of Pain).56
• Physical dependence or tolerance are not synonymous with addiction (as does the Federation of State Medical 
Board’s Model Policy for the Use of Controlled Substances for the Treatment of Pain).56
The Imperative to Evaluate Pain Policy
Many international and national authorities, including the World Health Organization (WHO), the International 
Narcotics Control Board (INCB), the Institute of Medicine (IOM), the American Cancer Society (ACS), 
and the National Institutes of Health (NIH), have called attention to the inadequate treatment of pain and 
have concluded that it is due in part to drug abuse control policies that impede medical use of opioids.a   These 
authorities have recommended evaluation and improvement of pain policies.  For example, following a review of 
the reasons for inadequate cancer pain relief, the INCB asked all governments in the world to:
“...examine the extent to which their health-care systems and laws and regulations permit the use of opiates for medical 
purposes, identify possible impediments to such use and develop plans of action to facilitate the supply and availability of 
opiates for all appropriate indications” (p. 17).57
The WHO has stated that better pain management could be achieved throughout the world if governments used 
evaluation guidelines to identify and overcome regulatory barriers to the availability and appropriate medical use 
of opioid analgesics.46
In the U.S., the IOM Committee on Opportunities in Drug Abuse Research called for:
“...additional research on the effects of controlled substance regulations on medical use and scientific research.  
Specifically, these studies should encompass the impact of such regulations and their enforcement on prescribing 
practices and patient outcomes in relation to conditions such as pain...[and]... for patients with addictive disorders”  
(p. 259).58
The IOM Committee on Care at the End of Life recommended:
“...review of restrictive state laws, revision of provisions that deter effective pain relief, and evaluation of the effect 
of regulatory changes on state medical board policies...” [and] “reform [of] drug prescription laws, burdensome 
regulations, and state medical board policies and practices that impede effective use of opioids to relieve pain and 
suffering” (p. 198, 267).2
In 2001, the ACS stated that “…additional and sustained efforts are needed to ensure that new barriers are not 
erected and that adequate pain relief for cancer patients is assured” (p. 3).59  The NIH concluded that “Regulatory 
barriers need to be revised to maximize convenience, benefit, and compliance…” (p. 15).4
a The Agency for Healthcare Policy and Research is no longer included as an authoritative source because its clinical practice 
guidelines on acute pain (1992) and cancer pain (1994) have been withdrawn.
INTRoDuCTIoN
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This Progress Report Card (Progress Report Card 2006), supported by grants from the 
American Cancer Society and the Susan G. Komen Breast Cancer Foundation, and through 
a cooperative agreement with the Lance Armstrong Foundation, is the latest in a sequence 
of reports60 developed to evaluate state policies that affect pain management.b   It is a tool 
that can be used by government and non-government organizations to achieve more positive 
and consistent state policy on the medical use of controlled substances for pain management 
(acute, cancer, and non-cancer pain), palliative care, and end-of-life care.  The policy changes 
that are needed do not interfere with the underlying principle that opioid analgesics may only 
be provided for legitimate medical purposes by licensed healthcare practitioners in the course of 
their professional practice.  The policy research terms used in this report are defined in Table 1.
Table 1: Policy Research Terms
Pain policy refers to federal or state policy that relates to pain management, and is generally found in 
two categories:  
Pain-specific policies directly address pain and its management, such as medical board pain 
treatment guidelines.  
Pain-related policies do not directly address pain management but contain provisions that 
could ultimately affect its treatment, such as state acts that address generally the prescribing and 
dispensing of controlled substances.
Within pain policies are: 
Provisions: policy language that was identified as satisfying an evaluation criterion, and include  
positive provisions, which are those parts of a policy identified in the evaluation that have 
the potential to enhance pain management, and
negative provisions, which are those parts of a policy identified in the evaluation that have 
the potential to impede pain management.
Policy change is the addition or removal of provisions; sufficient policy change in a state will 
produce a grade change for that state.
Policy Types
law is a broad term that refers to rules of conduct with binding legal force adopted by a legislative or 
other government body at the international, federal, state or local levels.  Law can be found in treaties, 
constitutional provisions, decisions of a court, and include both statutes and regulations.  The most 
common laws are the statutes enacted by a legislature, such as an Intractable Pain Treatment Act 
(IPTA), or those that create prescription monitoring programs or pain advisory councils, or license 
healthcare facilities.
Regulation is an official policy issued by an agency of the executive branch of government pursuant 
to statutory authority.  Regulations are found in the state administrative code.  Regulations have 
binding legal force and are intended to implement the administrative policies of a statutorily-created 
agency. For example, regulations issued by licensing boards according to a state’s administrative 
procedures statute govern professional conduct, and establish what conduct is or is not acceptable 
for those regulated by the agency (such as physicians, pharmacists, and nurses).  Regulations of state 
agencies may not exceed the agency’s statutory authority.
Guideline means an officially-adopted policy issued by a government agency to express the agency’s atti-
tude about, or position on, a particular matter.  Although guidelines do not have binding legal force, they 
may help those regulated by an agency to better understand the regulating agency’s standards of practice.  
A number of state medical boards have issued guidelines regarding the medical use of opioid analgesics, 
which describe conduct the board considers to be within the professional practice of medicine; some 
pharmacy and nursing boards have issued similar guidelines.  “Guidelines” may also include an officially 
adopted position statement that appears in a position paper, report, article, letter or agency newsletter. 
b Federal policy was not included in this report card because such policy does not regulate professional practice. 
Evaluation of federal policies is available in the Evaluation Guide 2006, at www.painpolicy.wisc.edu.
WHy A PRoGRESS REPoRT CARD?
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Based on findings from three separate PPSG evaluations of state pain policies,61-63 each state has been assigned 
a grade for 2000, 2003 and 2006.  To measure progress, the PPSG compared states’ grades from 2006 with their 
grades from 2000 and 2003. 
The Progress Report Card 2006 is the result of policy research and is not a “position” about a state’s pain policies.  
The use of a single index to compare states can draw the attention of state policy-makers and healthcare  
professionals to the need to evaluate and improve the regulatory policy environment for pain management.c   
We recognize that a grade may oversimplify a state’s policies.  Therefore, we are making available detailed 
information about the specific statutes, regulations, and guidelines that PPSG evaluated in each state; these are 
in the Evaluation Guide 2006, which is the companion document to the Progress Report Card 2006.  In addition,  
the PPSG provides the complete text of each state’s pain-specific (but not pain-related) policies on its website  
at www.painpolicy.wisc.edu/matrix.htm  
Method to Evaluate Pain Policies
The Evaluation Guide 2006 describes methods that PPSG has developed with peer review to evaluate pain policies 
using a central principle and criteria as well as procedures to collect policies, and identify and quantify relevant 
policy provisions.63  Based on feedback about previous reports, the evaluation methodology used for this report 
was expanded to include a broader variety of policies (e.g., those governing osteopathic practice, licensure of 
healthcare facilities, and education of healthcare professionals) (see the Evaluation Guide 2006 for a complete 
description of the changes to the evaluation methodology).  
The Central Principle of Balance
The Central Principle of Balance, which is defined in Table 2, guides this evaluation of pain policies.  The main 
idea is that drug control and professional practice policies and their implementation should be balanced so efforts 
to prevent diversion and abuse do not interfere in the medical use of opioid analgesics for patient care.
Table 2: The Central Principle of Balance
The Central Principle of Balance represents a dual obligation of governments to establish a system of controls to 
prevent abuse, trafficking, and diversion of narcotic drugs while, at the same time, ensuring their medical availability.  
Medical availability
•  While opioid analgesics are controlled drugs, they are also essential drugs and are absolutely necessary for the relief of pain. 
•  Opioid analgesics should be accessible to all patients who need them for relief of pain.  
•  Governments must take steps to ensure the adequate availability of opioids for medical and scientific purposes, including: 
–  empowering medical practitioners to provide opioids in the course of professional practice, 
–  allowing them to prescribe, dispense and administer according to the individual medical needs of patients, and 
–  ensuring that a sufficient supply of opioids is available to meet medical demand.
Drug control
•  When misused, opioids pose a threat to society. 
•   A system of controls is necessary to prevent abuse, trafficking, and diversion, but the system of controls is not intended 
     to diminish the medical usefulness of opioids, nor interfere in their legitimate medical uses and patient care. 
(Adapted from Pain & Policy Studies Group.  Achieving Balance in Federal and State Pain Policy: A Guide to Evaluation,  
Third Edition. Madison, WI: Pain & Policy Studies Group, University of Wisconsin Paul P. Carbone Comprehensive 
Cancer Center; 2006.)
c The adequacy of controls to prevent diversion and abuse of controlled substances is also a valid topic for the evaluation of policy.  
The purpose of this document is to evaluate policies affecting drug availability, medical practice, and pain management, rather than 
drug abuse prevention and control.
WHy A PRoGRESS REPoRT CARD?
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Appendix A documents the sources of legal and medical authority from which the PPSG derived the Central 
Principle of Balance.
The Evaluation Criteria
The PPSG developed 16 criteria based on the Central Principle of Balance.  They are divided into two categories 
and are used to identify positive and negative provisions in all state statutes, regulations, and guidelines and 
official governmental policy statements (see Table 3 for a list of the individual criteria).d   The state grades 
measure the quality of state pain policy in relation to the Central Principle of Balance, and are based on the 
frequency of provisions in a state that meet the evaluation criteria; the higher the grade, the more balanced are a state’s 
policies regarding opioid availability and pain management.  
To assign grades, the PPSG: (1) identified the positive and negative policy provisions in each state, and (2) 
assigned grades based on the total number of provisions, the average, and the standard deviation.  Appendix B 
contains a complete explanation of the grading methodology.
d The District of Columbia is treated as a state.
Table 3: Criteria used to Evaluate State Pain Policies
Positive provisions: Criteria that identify policy language with the potential  
to enhance pain management
1. Controlled substances are recognized as necessary for the public health
2  Pain management is recognized as part of general medical practice
3. Medical use of opioids is recognized as legitimate professional practice
4. Pain management is encouraged
5. Practitioners’ concerns about regulatory scrutiny are addressed
6. Prescription amount alone is recognized as insufficient to determine the legitimacy of prescribing
7. Physical dependence or analgesic tolerance are not confused with “addiction”
8. Other provisions that may enhance pain management
Category A: Issues related to healthcare professionals
Category B: Issues related to patients
Category C: Regulatory or policy issues
Negative provisions: Criteria that identify policy language with the potential  
to impede pain management
  9. Opioids are considered a treatment of last resort
10. Medical use of opioids is implied to be outside legitimate professional practice
11. Physical dependence or analgesic tolerance are confused with “addiction”
12. Medical decisions are restricted
Category A: Restrictions based on patient characteristics
Category B: Mandated consultation
Category C: Restrictions regarding quantity prescribed or dispensed
Category D: Undue prescription limitations
13. Length of prescription validity is restricted
14. Practitioners are subject to additional prescription requirements
15. Other provisions that may impede pain management 
16. Provisions that are ambiguous
Category A: Arbitrary standards for legitimate prescribing
Category B: Unclear intent leading to possible misinterpretation
Category C: Conflicting (or inconsistent) policies or provisions
WHy A PRoGRESS REPoRT CARD?
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Two capsules are provided to elucidate the relevance of selected evaluation criteria, showing how policy relates to 
healthcare practice and patient care.
Capsule 1: Fear of Regulatory Investigation for Prescribing opioids 
Evaluation Criterion #5
Patients
“With everything that is out there with these medicines, aren’t you and your license in danger for prescribing this kind of 
medicine?” (Statement from patient in a large university chronic pain program.)
Physicians 
Some physicians report that concern about being investigated by regulatory and licensing agencies when prescribing opioid 
medications for patients, including those with cancer pain or chronic non-cancer pain, leads them to prescribe lower doses 
or quantities of pain medication and to authorize fewer refills.64,65
Regulators 
Some members of state medical boards that license and investigate physicians declare that prescribing opioids to patients 
with chronic non-cancer pain should be discouraged or investigated.66,67
State Pain Policies 
In the last decade, 39 state legislatures and medical boards have adopted policies that recognize and address physicians’ 
concerns about being investigated for prescribing opioid pain medications.
Conclusion
Despite a growing effort by policymakers and regulators, the fear of regulatory scrutiny remains a significant impediment to 
pain relief and will take years of further policy development, communication, and education to overcome. 
Capsule 2: Confusion about Addiction-Related Terms 
Evaluation Criteria #7 & #11
Patients 
“…I was openly accused of being an ‘addict’ and of falsely reporting chronic pain just to obtain prescription drugs.”68   
Some cancer patients refuse pain treatment for fear of becoming addicted.69,70 
Physicians and Pharmacists
Some physicians express concern that addiction or drug abuse will develop when prescribing to patients with cancer or 
chronic non-cancer pain.65,71  Some pharmacists lack knowledge of the crucial distinction between addiction, physical 
dependence, and tolerance.72,73
Regulators 
Some state medical regulators do not understand the meaning of “addiction,” but educational efforts have led to 
improvements in their knowledge of this concept.66,67
State Pain Policies 
In the last decade, 36 state healthcare regulatory boards have adopted policies that correctly define addiction-related terms.  
Despite this progress, 16 states still have inaccurate definitions that would allow pain management to be confused with 
addiction.63,74
Conclusion
Confusion about addiction leads to overestimation of its prevalence and is a significant impediment to pain relief.  
Recently-adopted state policies and improved knowledge of regulators are steps in the right direction; however, a much 
greater systematic effort will be needed to clarify policy and educate policy makers, healthcare practitioners and patients 
so that concerns about addiction are based on an accurate understanding of this disease and do not interfere with pain 
management. 
Readers are referred to the Evaluation Guide 2006, a companion to this report, for a more detailed discussion of 
the imperative to evaluate policy, the Central Principle of Balance, the evaluation criteria, the method used to 
evaluate state policies, and the text of the policy provisions that were identified in each state.
WHy A PRoGRESS REPoRT CARD?
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A B+ B C+ C D+ D F
Michigan
Virginia
Alabama
Kansas
Nebraska
New Mexico
Oregon
Vermont
Arizona
Arkansas
Florida
Hawaii
Idaho
Iowa
Kentucky
Maine
Maryland
Massachusetts
Minnesota
North 
Carolina
North Dakota
Ohio
Rhode Island
South Dakota
Utah
Washington
West Virginia
Wisconsin
Alaska
Colorado
Connecticut
Delaware
Dist. of 
Columbia
Indiana
Mississippi
Missouri
Montana
New 
Hampshire
Oklahoma
Pennsylvania
South 
Carolina
Wyoming
California
Illinois
Louisiana
Nevada
New Jersey
New York
Tennessee
Texas
Georgia None None
MAkING THE GRADE:  
HoW Do THE STATES RATE?
State Grades for 2006 : States’ grades for 2006 are presented in Figure 1 and Table 4.
Figure 1:  
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Highlights of the 2006 Grades
• 16% of states received an average grade of C, while 82% scored above a C and only 2% fell below the 
average.
• Michigan and Virginia were the only states to receive an A; no state received a D or F.
• Only two distinct regional patterns emerged: States in the northern Midwest (Iowa, Minnesota, North 
Dakota, South Dakota and Wisconsin) received Bs, as did three Northwestern states (Idaho, Oregon, and 
Washington); 
• The three states with the largest population (California, New York, and Texas), representing 
approximately a quarter of the U.S. population, each earned average grades of C.
Table 4: State Grades for 2006
STATES 2006 GRADES STATES
2006 
GRADES
AL B+ MT C+
AK C+ NE B+
AZ B NV C
AR B NH C+
CA C NJ C
CO C+ NM B+
CT C+ NY C
DE C+ NC B
DC C+ ND B
FL B OH B
GA D+ OK C+
HI B OR B+
ID B PA C+
IL C RI B
IN C+ SC C+
IA B SD B
KS B+ TN C
KY B TX C
LA C UT B
ME B VT B+
MD B VA A
MA B WA B
MI A WV B
MN B WI B
MS C+ WY C+
MO C+
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Did Grades Change from 2000 to 2006?
To evaluate changes that occurred over the last six years, 2006 grades were compared with the 2000 and 2003 
gradese (see Table 5). 
Table 5: State Grades for 2000, 2003, and 2006
STATES
2000 
GRADES
2003 
GRADES
2006  
GRADES
STATES
2000  
GRADES
2003  
GRADES
2006  
GRADES
AL B B B+ MT C+ C+ C+
AK C C+ C+ NE B+ B+ B+
AZ B B B NV D+ C C
AR C+ C+ B NH C C+ C+
CA C C C NJ D D+ C
CO C C C+ NM B B+ B+
CT C C C+ NY D C C
DE C+ C+ C+ NC B B B
DC D+ D+ C+ ND C C B
FL B B B OH B B B
GA D+ D+ D+ OK C+ C+ C+
HI C C B OR C+ C+ B+
ID C C+ B PA C+ C+ C+
IL C C C RI D+ D+ B
IN C C+ C+ SC C+ C+ C+
IA C+ B B SD B B B
KS C+ B+ B+ TN D C C
KY D+ C+ B TX C C C
LA C C C UT C+ C+ B
ME B B B VT C C+ B+
MD C+ B B VA B B A
MA C B B WA B B B
MI B A A WV C+ B B
MN C+ C+ B WI C C+ B
MS C C C+ WY C C C+
MO D+ C+ C+
•  Almost half (49%) of states received above a C in 2000, increasing to 67% in 2003 and 82% in 2006.  
•  Michigan and Virginia received an A in 2006.
•  No state’s grade decreased from 2000 to 2006.
e 2000 and 2003 grades were re-calculated using the 2006 methodology to allow comparison and measure progress over time (see 
Appendix B: Method to Assign Grades); the grades in this report are in some cases not the same as those contained in the first, and 
now obsolete, Progress Report Card.
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How Did Grades Change from 2003 to 2006?
• 35 of 51 states (69%) changed their policies; the policy changes were sufficient in 19 of these states to 
produce a positive grade change.
• Of the 19 states that improved, Rhode Island had the greatest improvement, moving from a D+ to a B.  
Although a positive provision was added to the state Intractable Pain Treatment Act (Criterion #3; see 
Table 3), the improvement was due primarily to the repeal from statute of six restrictive or ambiguous 
provisions: Criteria #10, #11, #13, #14, #16 (Category A), and #16 (Category B) (see Table 3 for a 
description of the criteria).  
• 32 states made no policy changes sufficient to make a difference in their grade (see Table 6).
Table 6:  Grade Change in State Pain Policy  
Between March 2003 and March 2006
Positive Change –19 states No Change – 32 states
Alabama Alaska
Arkansas Arizona
Colorado California
Connecticut Delaware
District of Columbia Florida
Hawaii Georgia
Idaho Illinois
Kentucky Indiana
Minnesota Iowa
Mississippi Kansas
New Jersey Louisiana
North Dakota Maine
Oregon Maryland
Rhode Island Massachusetts
Utah Michigan
Vermont Missouri
Virginia Montana
Wisconsin Nebraska
Wyoming Nevada
New Hampshire
New Mexico
New York
North Carolina
Ohio
Oklahoma
Pennsylvania
South Carolina
South Dakota
Tennessee
Texas
Washington
West Virginia
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Interesting New Policies
In 2006, we expanded our evaluation to other policies.  Although those policies did not contribute greatly to the 
positive grade changes observed between 2003 and 2006, the following information is of interest:
• 9 states (18%) have adopted laws that either mandate or encourage healthcare practitioners to obtain 
continuing education about pain management issues.
• 26 states (51%) have adopted regulations establishing pain management standards for healthcare facilities, 
including hospitals, hospices, and nursing homes.
• In those states where the osteopathic board is separate from the medical board, 38% have adopted policies 
that encourage the appropriate use of controlled substances for pain management.
Reasons for the Improved Grades
State grades for balanced policy continued to improve significantly from 2003 to 2006.  As in the previous 
Progress Report Card (Progress Report Card 2003), the driving force for positive policy change was state healthcare 
regulatory boards that adopted several types of policies encouraging pain management or palliative care.  Less 
frequent sources of positive policy change were legislative adoption of pain-specific statutes and repeal of 
restrictive or ambiguous language.
HealTHcare reGulaTory Board PolicieS
The Federation’s Model Policies  
To promote consistency in state medical board policy, in 1998 the Federation of State Medical Boards of the U.S. 
(the Federation) adopted Model Guidelines for the Use of Controlled Substances for the Treatment of Pain (Model 
Guidelines).75  In May 2004, the Federation’s House of Delegates unanimously adopted a revision of the Model 
Guidelines, called the Model Policy for the Use of Controlled Substances for the Treatment of Pain (Model Policy).56  The 
revision is substantially similar to the 1998 guidelines, but additionally recommends that state boards consider 
failure to treat pain as subject to professional discipline.  Many state medical regulatory boards have participated 
in pain management workshops sponsored by the Federation and the PPSG and subsequently adopted the Model 
Guidelines or Model Policy to encourage better pain management and to address physicians’ fear of investigation.53,76 
The trend of state medical boards adopting policies on pain management has resulted in positive changes in state 
pain policies77 and also in efforts to communicate them to practitioners and the public.78,79
As of March 2006, a total of 28 states had adopted either the Model Guidelines or Model Policy in whole or in  
part.f  Twelve states (Colorado, Connecticut, Idaho, Massachusetts, Missouri, Nebraska, North Carolina, 
Oklahoma, Utah, Vermont, Virginia, and West Virginia) adopted medical board regulatory policies based on the 
Federation’s Model Policy.  The Model Policy does not have any negative provisions; states that adopt it receive the 
greatest number of positive provisions (9) from a single policy: Criteria #2, #3, #4, #5, #6, #7, (see Table 3 for a 
description of the criteria), as well as three provisions that satisfy Criterion #8 (see Appendix D for a description 
of Criterion #8 categories).
Three state medical board regulatory boards (Hawaii, Kentucky, and Michigang) approved policies based on the 
Federation’s previous Model Guidelines. States that fully adopt the Model Guidelines are credited with eight positive 
provisions and no negative provisions: Criteria #2, #3, #4, #5, #6, #7 (see Table 3), and two instances of Criterion 
#8 (see Appendix D for a description of Criterion #8 categories).
Finally, medical boards in four other states (California, the District of Columbia, Oregon, and Wyoming) had 
unique policies that were not based on either of the Federation’s models. These policies are distinct from one-
another and contain provisions that meet a range of positive criteria. 
f These states are Alabama, Arizona, Colorado, Connecticut, Florida, Hawaii, Idaho, Kansas, Kentucky, Maine, Massachusetts, 
Michigan, Missouri, Nebraska, Nevada, New Hampshire, New York, North Carolina, Oklahoma, Pennsylvania, South Carolina, 
South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, and West Virginia.
g Michigan’s pain management policy was a product of collaboration between the medical and osteopathic boards.
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Pharmacy Board Policies  
Three state pharmacy boards (Florida, Michigan, and Wisconsin) adopted policies relating to pain management; 
those in Florida and Michigan were based on the Federation’s model policies.  Collectively, the following criteria 
were fulfilled: Criteria #2, #3, #4, #5, #7 (see Table 3), and four instances of Criterion #8 (see Appendix D for a 
description of Criteria #8 categories).
Joint Board Policies
Four states (Florida, Michigan, Minnesota, and New Mexico) approved joint policy statements relating to the 
use of controlled substances for the treatment of pain, which were developed collaboratively by several regula-
tory boards such as medicine, osteopathy, pharmacy, and nursing.  These policies, which represent a consensus of 
boards that govern healthcare practice, are a unique and credible way to emphasize the importance of multidisci-
plinary treatment of pain.  Collectively, the following positive provisions were added: Criteria #2, #3, #4, #5, #7 
(see Table 3), and numerous instances of Criterion #8 (see Appendix D for a description of Criterion #8 categories).
Pain-SPeciFic STaTuTeS
Arkansas adopted an Intractable Pain Treatment Act (IPTA) and Hawaii adopted Pain Patient’s Bill of Rights 
legislation, both of which added a total of 17 positive provisions.   Although three negative provisions were added 
as well, these statutes are improvements over similar past legislation containing numerous instances of restrictive 
or ambiguous policy language.
rePeal oF reSTricTive or aMBiGuouS lawS
Positive policy change also occurred when states repealed negative provisions from laws that establish prescription 
monitoring programs, short prescription validity periods, required consultation, and opioids as a treatment of  
last resort.
changes in Prescription Monitoring Programs
Two states (California and New York) repealed their requirement for a government-issued multiple- or single-
copy prescription form for Schedule II controlled substances only (although New York’s requirement included 
Benzodiazepines in Schedule IV) (Criterion #14).  California replaced its triplicate program with an Electronic 
Data Transfer (EDT) system that does not require a special government-issued prescription form; California’s 
EDT program requires the use of a serialized security form for medications in Schedules II-V.   New York expanded 
its EDT program with an easy-to-obtain single-copy government-issued form for all prescription medications, 
including all controlled substances.  Such changes are thought to eliminate a barrier to pain management 
because they reduce practitioners’ reluctance to obtain and use the forms, are a less intrusive method to monitor 
physicians’ prescribing, and do not stigmatize the Schedule II medications that are so important for managing 
severe pain.  One state (Texas) continues to have single-copy prescription form requirement only for  
Schedule II controlled substances.  In addition, we found that some policies establishing prescription monitoring 
programs include language recognizing that the program is not intended to interfere with medical practice, thus 
directly supporting the Central Principle of Balance.
restrictive Prescription validity Period
Two states modified overly restrictive prescription validity periods of less than two weeks (Criterion #13) from 
controlled substances statutes and/or regulations.  Rhode Island eliminated its 7-day period; Texas eliminated a 
7-day period from a regulation, but it remains present in the Controlled Substances Act.  Such changes eliminate 
an unrealistically short number of days within which the prescription must be dispensed following its issue.  Short 
validity periods can impede a patient’s ability to obtain medications without having to make sometimes expensive 
arrangements, especially when travel, slow mail delivery, or other extenuating circumstances exist.  Exceeding a 
prescription’s validity period necessitates issuance of a new prescription and possibly a return visit to the physician. 
Five states, including Texas, continue to have a validity period of less than two weeks.h 
MAkING THE GRADE:  
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Mandated consultation Provisions
Five states (California, Colorado, Idaho, Oregon, and Vermont) repealed provisions mandating that physicians 
always consult with specialists when using controlled substances to treat patients with pain if they want immunity 
from disciplinary sanction (Criterion #12: Category B).  Although there is no question that physicians should 
seek consultation when needed, such a requirement is not necessary for every case, especially if the practitioner 
is knowledgeable about pain management.  In addition, such a requirement does not allow for patients who need 
immediate treatment.  Ten states currently mandate consultation under certain circumstances when using opioids 
to treat patients with pain, including California and Colorado that retained this provision in other policies.i 
opioids as a last resort
 Seven states (Colorado, Kentucky, New Mexico, North Dakota, Rhode Island, Virginia, and West Virginia) 
repealed language that either required that patients undergo other treatment modalities before being prescribed 
opioids (Criterion #9) or suggested that medical use of opioids is considered, as a matter of policy, a treatment of 
last resort (Criterion #16: Category B).  Currently, 21 states have policies that characterize opioids as a treatment 
of last resort.j 
Some Negative Policy Changes
Policy change, but no grade changes, occurred because a few states added restrictive or ambiguous policy language 
between 2003 and 2006.  Six states added the following negative provisions: 
• Restricts prescribing to patients with an addictive disease (Arkansas), 
• Suggests that physicians would not qualify for immunity if they prescribe opioids as a treatment of first 
choice for patients who present initially with severe pain (Arkansas),
• Mandates consultation (District of Columbia), 
• Within the “Pain Patient’s Bill of Rights,” permits physicians to refuse to prescribe opioid medications, 
which appears to conflict with the standard recognizing that opioids are necessary for public health and are 
a part of medical practice; this language falls short of providing any patient rights and thus may establish a 
false expectation for adequate pain management (Hawaii),
• Restricts the quantity of medication prescribed or dispensed (Louisiana), 
• Permits pharmacists to refuse to fill a prescription if potential harm is based solely on the quantity of 
medication prescribed (North Carolina), 
• Although adopting the Federation’s Model Policy, additional policy language contradicts the flexibility 
standard inherent in the policy (Utah).
i These states are Arizona, California, Colorado, District of Columbia, Mississippi, Nevada, New York, Ohio, Oklahoma,  
and Rhode Island.
j These states are Arizona, Arkansas, California, Colorado, District of Columbia, Georgia, Louisiana, Maryland, Minnesota, Missouri, 
Mississippi, Montana, Nevada, New Jersey, Ohio, Oregon, Tennessee, Texas, Vermont, Washington, and West Virginia.
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Michigan and Virginia now have the most balanced pain policies in the country.  In the last six 
years, these two states took advantage of the Federation’s Model Guidelines and Model Policy, and 
repealed all excessively restrictive and ambiguous policy.  This achievement does not mean the work 
is finished, because policy needs to be implemented (see next section).  There is no ceiling on policy 
quality, so states with high grades should continue to explore how additional policy can help to 
improve access to pain management while avoiding the adoption of negative policies. 
Since 2003, in the rest of the country, legislatures and healthcare regulatory agencies in 19 states 
modified their policies sufficiently to improve their grade for Balance.  Five of those states (Idaho, 
Kentucky, New Jersey Vermont, and Wisconsin) improved their pain policies between 2000 and 
2003, and did so again between 2003 and 2006, demonstrating that some states have continuing 
efforts to enhance pain policies that can affect professional practice and patient care.  There 
have been no states since 2000 where changes in policy result in a reduced grade.  Overall, the 
evidence in this report paints a positive picture of progress towards Balance.  Looking ahead, 
several states have special opportunities to achieve the highest grade for balanced policies; other 
states face special challenges.
Implications for Future Policy Change Actions
Special opportunities.  Some states are in a unique position of being able to achieve significant 
policy change either by adopting positive policy or repealing restrictions.  Alabama, Alaska, 
Maine, North Dakota, and Wisconsin currently have no restrictive or ambiguous language in state 
pain policies.  These states could achieve an A simply by adopting additional positive policies.  
Five other states (Kansas, Nebraska, New Mexico, Oregon, and Vermont) would have received  
an A in 2006 had one or two restrictive or ambiguous provisions been repealed.
Special challenges.  In 2006, over 80% of the states achieved a grade above a C; this was a sub-
stantial improvement since 2003, when two-third of states had a grade exceeding the average.  
Such progress is significant, but for states to achieve more balanced and consistent pain policy, 
they face the challenge of removing many long-outdated negative provisions from state statutes, 
some of which have been present for 30 years or more.  Negative provisions are not a necessary 
part of the laws needed for drug control or the regulation of professional practice.  To be sure, 
states may enact laws or other governmental policies that are stricter than federal law, and should 
be free to experiment and differ in their approaches to public policy.  However, it is necessary to 
ensure that all such policies are balanced and that patient care decisions requiring medical exper-
tise are not unduly restricted by governmental regulation aimed instead at preventing drug abuse.  
For example, in the last six years there was only a 13% reduction in negative provisions from the 
nearly 200 that were present in 2000, compared to almost a 60% increase in positive provisions 
during the same period; this raises a question as to whether repeal of negative provisions in 
statutes is receiving less attention compared to efforts with professional licensing boards to adopt 
positive policy.  Appendix E shows the number of states with statutes, regulations, or guidelines 
or policy statements that contain language meeting criteria for both positive and negative 
provisions.  The presence of any of these provisions in a particular state can be determined by 
consulting the Evaluation Guide 2006.
A particular challenge may be in those states that have a considerable number of positive 
provisions but also have many negative provisions.k  In the last three years, California, New 
York, and Texas repealed restrictive legislative language, but such changes have not improved 
their grade because of the large number of negative provisions remaining.  For these states, there 
must be a continued focus on reducing the number of restrictive or ambiguous provisions for any 
positive grade change to occur.  
Finally, 47% of states will need to repeal restrictive provisions and adopt additional positive 
language to achieve a grade of A.  
CuRRENT STATuS oF BAlANCE  
IN STATE PAIN PolICy
k These states are California, New Jersey, New York, Tennessee, and Texas.
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Overall, the momentum for positive change in state pain policy continues into 2006, 
apparently in response to increasing national recognition that improving or removing 
provisions that can influence professional practice and patient care is an important step in 
improving pain management for patients with cancer, HIV/AIDS, and other diseases.  The 
use of policy evaluation resources and model policies by state groups to guide positive policy 
change efforts is apparent.
This trend has even occurred during a period of increase in the abuse and diversion of 
opioid pain medications.80-82  In the future, it will be important that efforts by governments 
and healthcare professionals to address drug abuse not interfere with legitimate medical 
practices and patient access to appropriate pain care.  A public health approach to preventing 
prescription drug abuse is needed and is compatible with the Central Principle of Balance.83  
A more balanced national policy can be achieved and maintained if policymakers and 
advocates work together, use the Central Principle as a guide, and take advantage of the policy 
resources that are available.  The PPSG contribution to this process is policy research, model 
development, and technical assistance to government agencies and groups working to improve 
Balance in pain policy.
CoNCluSIoN
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1. establish a policy evaluation mechanism 
The extent to which a state’s policies are balanced or unbalanced can either contribute to 
or detract from a positive professional practice and drug regulatory environment for pain 
management. Recognizing that the improvement of state pain policies ultimately requires 
government concurrence, a number of states have successfully developed ad hoc policy 
evaluation mechanisms that are associated with state government; these include task forces, 
commissions, advisory councils, and summit meetings.84-86  The terms of reference for such a 
body should include evaluation of the state’s pain policies, the membership should include 
governmental and non-governmental stakeholders, and dedicated staffing should be available.  
The guidance available from authorities can help to make the case for establishing a task force 
to examine pain policy; these sources can be found in the section of this report, entitled “The 
Imperative to Evaluate Policy,” and in the Evaluation Guide 2006.
Once established, a state task force can take advantage of several resources to review state 
policy, including: (a) internet access to the full text of its own and every other state’s pain-
specific policies (www.painpolicy.wisc.edu/matrix.htm), (b) a State Profile that identifies each 
specific provision found during the PPSG 2006 evaluation, arranged according to the policy in 
which it was found and the criterion it satisfied (contained in the Evaluation Guide 2006), and 
(c) the Progress Report Card 2006, which shows the distribution and details about the grades for 
each state for 2000, 2003, and 2006.   
The task force might be interested in learning, for example, how its grade compares to other 
states, in particular contiguous states.  The task force might also be interested in which positive 
or negative criteria are fulfilled by the state’s current policy (from the Evaluation Guide 2006 
State Profiles section) and how this compares with the policies from other states.  Appendix E 
shows the total number of states with pain policies that fulfill each evaluation criterion.  Such 
comparisons could answer such questions as:
• Does my state policy specifically encourage pain management (as it does in 38 states),  
or not?  
• Does my state policy directly address practitioners’ fears of being investigated (as it 
does in 39 states), or not?  
• Does my state policy define addiction so that it could be confused with physical 
dependence that may develop when using opioids to treat pain (as it does in 16 states), 
or not.  
• Does my state policy contain provisions that create unclear standards or requirements 
for practitioners when treating a patient with pain (as it does in 22 states), or not?
After a state’s pain policies have been studied, corrective proposals can be developed.  The 
main resource to assist with this process is the Evaluation Guide 2006, which contains a section 
entitled “Example Language to Improve Pain-Related Policy,” and is available on the internet 
at www.painpolicy.wisc.edu.  This section includes relevant language from the Federation’s 
Model Policy and other models, and example language from other states.
RECoMMENDATIoNS FoR  
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2. Make a commitment to implementing policy 
Policy change without implementation has little value.  Balanced policy must also be understood and respected as 
such.  Many licensed practitioners are not fully aware of the policies that govern controlled substances prescribing 
and pain management.73,87  Professional licensing boards should disseminate widely and frequently the policies 
that affect practitioners and pain management.  Once a state’s policy has been improved, it should also be 
communicated to those who implement the policy and are affected by it, including practitioners and the public, 
but also administrators, investigators and attorneys.  
The goal is to promote understanding that the state’s policy is to encourage pain management, and that healthcare 
professionals who responsibly provide controlled pain medications should have nothing to fear from regulatory  
or law enforcement agencies in the state.  For example, the medical licensure boards in North Carolina and  
Minnesota have excelled in their efforts to communicate pain management policy to licensed physicians.88-90   
The Maryland Board of Physician Quality Assurance has produced a videotape titled “A Sense of Balance:  
Treating Chronic Pain,”91 which is required viewing for new licensees.  Some states, such as Michigan and  
Texas, have adopted laws that require healthcare regulatory agencies to periodically educate their licenses  
about pain management issues.  Several state medical licensing boards, including those in Minnesota and Ohio, 
have sections on their websites that provide information to licensees about the use of controlled substances for 
pain management.
RECoMMENDATIoNS FoR  
IMPRovING STATE GRADES
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Appendix A: Authoritative Sources for the Central Principle of Balance
inTernaTional auTHoriTieS
united nations Single convention on narcotic drugs of 1961
“...the medical use of narcotic drugs continues to be indispensable for the relief of pain and suffering...adequate provision 
must be made [by governments] to ensure the availability of narcotic drugs for such purposes” (UN, 1977, p. 13).
“The Parties [national governments] shall take such legislative and administrative measures as may be necessary...to limit 
exclusively to medical and scientific purposes the production, manufacture...distribution... and possession of drugs” 
(UN, 1977, p. 18-19).
world Health organization
“Decisions concerning the type of drug to be used, the amount of the prescription and the duration of therapy are best 
made by medical professionals on the basis of the individual needs of each patient, and not by regulation”  
(WHO, 1996, p. 58).
“...those [drugs] that satisfy the health care needs of the majority of the population; they should therefore be available at 
all times in adequate amounts and in the appropriate dosage forms...”  
(WHO Expert Committee on Essential Drugs, 1998, p. 2).
“These [Evaluation] Guidelines can be used by governments to determine whether their national drug control policies 
have established the legal and administrative framework to ensure the medical availability of opioid analgesics, according 
to international treaties and the recommendations of the INCB and the WHO… [and] to encourage governments to 
achieve better pain management by identifying and overcoming regulatory barriers to opioid availability”  
(WHO, 2000, p. 1-2).
“…access to pain relief and palliative care services is often limited, even in high-resource settings, because of…excessive 
regulation of opioids…[and] urges Member States…to ensure the medical availability of opioid analgesics according to 
international treaties and recommendations of WHO and the International Narcotics Control Board” (WHO, 2004, 
pp. 3-6).
united nations economic and Social council
“Recognizes the importance of improving the treatment of pain, including by the use of opioid analgesics, as advocated by 
the World Health Organization, especially in developing countries, and calls upon Member States to remove barriers to 
the medical use of such analgesics, taking fully into account the need to prevent their diversion for illicit use”  
(UN, 2005, p. 2).
world Health assembly
“...to ensure the medical availability of opioid analgesics according to international treaties and recommendations of 
WHO and the International Narcotics Control Board and subject to an efficient monitoring and control system”  
(WHA, 2005, p. 3).
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naTional auTHoriTieS
controlled Substances act
“Many of the drugs included within this subchapter have a useful and legitimate medical purpose and are necessary to 
maintain the health and general welfare of the American people” (Title 21 Controlled Substances Act §801(1)).
drug enforcement administration
“This section is not intended to impose any limitations on a physician or authorized hospital staff to...administer or 
dispense narcotic drugs to persons with intractable pain in which no relief or cure is possible or none has been found 
after reasonable efforts” (Title 21 Code of Federal Regulations §1306.07(c)).
“The CSA requirement for a determination of legitimate medical need is based on the undisputed proposition that 
patients and pharmacies should be able to obtain sufficient quantities...of any Schedule II drug, to fill prescriptions.  A 
therapeutic drug should be available to patients when they need it...”  (53 Federal Register 50593, 1988).
“Preventing drug abuse is an important societal goal, but there is consensus, by law enforcement agencies, health care 
practitioners, and patient advocates alike, that it should not hinder patients’ ability to receive the care they need and 
deserve…Undertreatment of pain is a serious problem in the United States, including pain among patients with chronic 
conditions and those who are critically ill or near death. Effective pain management is an integral and important aspect 
of quality medical care, and pain should be treated aggressively…For many patients, opioid analgesics – when used as 
recommended by established pain management guidelines – are the most effective way to treat their pain, and often the 
only treatment option that provides significant relief…Drug abuse is a serious problem. Those who legally manufacture, 
distribute, prescribe and dispense controlled substances must be mindful of and have respect for their inherent abuse 
potential. Focusing only on the abuse potential of a drug, however, could erroneously lead to the conclusion that 
these medications should be avoided when medically indicated – generating a sense of fear rather than respect for their 
legitimate properties” (Drug Enforcement Administration, Last Acts et al. 2001).
continued
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Federation of State Medical Boards of the u.S.
“…principles of quality medical practice dictate that the people...have access to appropriate and effective pain relief...
physicians [should] view pain management as a part of quality medical practice for all patients with pain...All 
physicians should become knowledgeable about assessing patients’ pain and effective methods of pain treatment, as well 
as statutory requirements for prescribing controlled substances...controlled substances, including opioid analgesics, may 
be essential in the treatment of acute pain due to trauma or surgery and chronic pain, whether due to cancer or non-
cancer origins” (FSMB, 2004, p. 5).
“Physicians should not fear disciplinary action from the Board for ordering, prescribing, dispensing or administering 
controlled substances, including opioid analgesics, for a legitimate medical purpose and in the course of professional 
practice” (FSMB, 2004, p. 6).
national association of attorneys General
“…there is a consensus among law enforcement agencies, health care practitioners, and patient advocates that the 
prevention of drug abuse is an important societal goal that can and should be pursued without hindering proper patient 
care; and…it is crucial that public health, law enforcement, and government officials continue to develop strategies and 
methods to prevent the abuse and diversion of prescription drugs, while safeguarding the right of those suffering from 
severe and chronic pain to continue to have access to appropriate medications” (NAAG, 2003, p. 1)
“The National Association of Attorneys General encourages states to ensure that any such programs or strategies 
implemented to reduce abuse of prescription pain medications are designed with attention to their potential impact on the 
legitimate use of prescription drugs” (NAAG, 2003, p. 2).
“…the Attorney General should actively promote the concept of balance that legitimate law enforcement goals should be 
pursued without adversely affecting the provision of quality end-of-life care” (NAAG, 2003, p. 20)
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Appendix B: Method to Assign Grades
(1) Identification of provisions:  The positive and negative provisions in state pain policies in 2000  
and 2003 had already been identified for the Evaluation Guide 2000 and Evaluation Guide 2003.l    
The PPSG updated its policy database in using the methodology explained in the Evaluation Guide 
2006.  The criteria were then used to identify positive and negative provisions in policies current 
through March 2006.
(2) Grading: The grading method was established using the total number of positive and negative provisions 
identified with the new policy evaluation methodology explained in the Evaluation Guide 2006.m   
As a result of the methodology changes, the state grades in this report for 2000 and 2003 may be 
different from those contained in the previous Progress Report Card from 2003.n   Each provision was 
given equal weight.  
In 2000, the total number of positive provisions for all states ranged from 0 to 33; the average number of positive 
provisions per state was 10 and the standard deviation (the extent that the values deviate from the average) was 
6.  Despite the large range of total positive provisions, 44 states had 14 or fewer provisions, which represented 
extreme skewness.  To adjust for the fact that few states had a large number of positive provisions in 2000, we 
defined the grade of C by a range including, and extending a standard deviation below, the average – a C was 
earned by states having a total of 5 to 10 positive provisions.  Negative provisions ranged from 0 to 16, with 
an average of 4 and a standard deviation of 3.  The averages and standard deviations were used to calculate 
the grades.  The same grading system was then applied to the total number of positive and negative provisions 
contained in all states’ policies present in 2003 and 2006 (relevant policies present in 2006 are contained in the 
Evaluation Guide 2006); so, states’ grades in 2000, 2003, and 2006 are based on the same evaluation and grading 
methodology.
Grading System for Positive and Negative Provisions
Distribution for Positive Provisions Grade Distribution for Negative Provisions
1 or more standard deviations above the average A 0 provisions
Within 1 standard deviation above the average B Within 1 standard deviation below the average
Around the average C Around the average
1 or more standard deviations below the average D Within 1 standard deviation above the average
0 provisions F 1 or more standard deviations above the average
Each state’s separate grades for positive and negative provisions can be found in Appendix C and are averaged to 
arrive at a state’s final grade; unless otherwise specified, the term “grade” refers to the final average grade.   
Mid-point grades were calculated (B+, C+, D+), rather than rounding up or down, in an effort to reflect more 
precisely each state’s unique combination of positive and negative provisions.  For example, if a state received an 
A for positive provisions and a B for negative provisions, the final grade would be a B+.
l In 2006, we expanded our evaluation to include other types of policies.  Such policies would not have appeared in the 2000 or 2003 
Evaluation Guides.  However, we determined the adoption date for all policies new to the evaluation in 2006.  Those policies found 
to be in effect as of March 2000 were included in the calculation of grades for 2000.  As a result, the 2000 state grades are based on 
the contents of the policies new to the evaluation and those originally contained in the Evaluation Guides.  The same process was 
used to calculate grades for 2003, using all policies in effect as of March 2003.
m Grades for 2000 and 2003 are based on revisions to the information contained in the Evaluation Guides published in 2000 and 2003.
n The Progress Report Card from 2003 is now considered obsolete and has been removed from our website.
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Appendix C: State Grades for Positive and Negative Provisions–2000, 2003, and 2006
STATES (+) GRADE 2000 (+) GRADE 2003 (+) GRADE 2006 (-) GRADE 2000 (-) GRADE 2003 (-) GRADE 2006
AL C C B A A A
AK D D D B A A
AZ B A A B C C
AR C C A B B C
CA A A A F F F
CO B B B D D C
CT D D C B B B
DE C C C B B B
DC F F C B B B
FL A A A C C C
GA D D D C C C
HI D D A B B C
ID C C B C B B
IL D D D B B B
IN C C C C B B
IA C B B B B B
KS C A A B B B
KY D B B C C B
LA C C C C C C
ME C C C A A A
MD C B B B B B
MA C B B C B B
MI A A A C A A
MN C C B B B B
MS C C B C C C
MO C A A D D D
MT C B B B C C
NE A A A B B B
NV C B B D D D
NH D C C B B B
NJ C B A F F F
NM B A A B B B
NY C A A F F F
NC B B A B B C
ND C C C C C A
OH A A A C C C
OK A A A D D D
OR B B A C C B
PA C C C B B B
RI B B A F F C
SC B B B C C C
SD B B B B B B
TN C A A F F F
TX A A A F F F
UT B B B C C B
VT C B A C C B
VA B B A B B A
WA B B B B B B
WV B A A C C C
WI D D C B A A
WY D D C B B B
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Appendix D: How language from Healthcare Regulatory Policy  
has Fulfilled the Categories of Criterion #8
Model Policy Category A: Recognizes inadequate treatment of pain as subject to disciplinary action just as 
other substandard practices might be
Category A: Recognizes that the goals of pain treatment should extend beyond pain scores to 
include improvements in patient functioning and quality of life
Category A: Acknowledges need for treatment flexibility for physicians to respond to 
individual clinical circumstances, as long as their prescribing maintains the standards of good 
medical practice
Model Guidelines Category A: Recognizes that the goals of pain treatment should extend beyond pain scores to 
include improvements in patient functioning and quality of life
Category A: Acknowledges need for treatment flexibility for physicians to respond to 
individual clinical circumstances, as long as their prescribing maintains the standards of good 
medical practice
Pharmacy Board policies Category A: Identifies pseudoaddiction as an important barrier to the appropriate use of 
opioid analgesics
Category A: Acknowledges need for treatment flexibility for physicians to respond to 
individual clinical circumstances, as long as their prescribing maintains the standards of good 
medical practice
Category A: Recognizes the need for a multidisciplinary approach to pain management
Category C: Represents the principle of Balance, which states that efforts to reduce the abuse 
and diversion of controlled substances should not interfere with legitimate medical use
Joint Board policies Category A: Identifies concerns of drug diversion as an important barrier to access to 
appropriate pain relief
Category A: Recognizes inadequate treatment of pain as subject to disciplinary action just as 
other substandard practices might be
Category A: Recognizes the need for a multidisciplinary approach to pain management
Category A: Recognizes that the goals of pain treatment should extend beyond pain scores to 
include improvements in patient functioning and quality of life
Category A: Acknowledges need for treatment flexibility for physicians to respond to 
individual clinical circumstances, as long as their prescribing maintains the standards of good 
medical practice
Category A: Recognizes a practitioner’s responsibility to provide patient’s information about 
pain management and palliative care when considering treatment options
Category B: Recognizes that a patient’s prior history of drug abuse does not contraindicate 
appropriate pain management
Category C: Represents the principle of Balance, which states that efforts to reduce the abuse 
and diversion of controlled substances should not interfere with legitimate medical use
APPENDICES
28Progress Report Card 2006
Appendix E: Number of States in 2006 with Policy language  
Having Potential to Enhance or Impede Pain Management
Positive provisions Number of states
1.  Controlled substances are recognized as necessary for the public health 4
2.  Pain management is recognized as part of general medical practice 45
3.  Medical use of opioids is recognized as legitimate professional practice 51
4.  Pain management is encouraged 38
5.  Practitioners’ concerns about regulatory scrutiny are addressed 39
6.  Prescription amount alone is recognized as insufficient to determine the legitimacy of prescribing 31
7.  Physical dependence or analgesic tolerance are not confused with “addiction” 36
8.  Other provisions that may enhance pain management
Category A: Issues related to healthcare professionals 47
Category B: Issues related to patients 18
Category C: Regulatory or policy issues 39
Negative provisions Number of states
  9.  Opioids are considered a treatment of last resort 8
10.  Medical use of opioids is implied to be outside legitimate professional practice 13
11.  Physical dependence or analgesic tolerance are confused with “addiction” 16
12. Medical decisions are restricted
Category A: Restrictions based on patient characteristics 9
Category B: Mandated consultation 10
Category C: Restrictions regarding quantity prescribed or dispensed 9
Category D: Undue prescription limitations 6
13. Length of prescription validity is restricted 5
14. Practitioners are subject to additional prescription requirements 6
15. Other provisions that may impede pain management 3
16. Provisions that are ambiguous
Category A: Arbitrary standards for legitimate prescribing 17
Category B: Unclear intent leading to possible misinterpretation 22
Category C: Conflicting (or inconsistent) policies or provisions 9
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